Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharming Group ( (PHGUF) ) has provided an announcement.
Pharming Group has announced an Extraordinary General Meeting of Shareholders on March 4, 2025, to appoint Mr. Fabrice Chouraqui as Executive Director and CEO, succeeding Mr. Sijmen de Vries. The meeting will also address the approval of components of Mr. Chouraqui’s remuneration package. This leadership transition is crucial for Pharming’s continued growth and strategic direction, as the company aims to strengthen its position in the biopharmaceutical industry, which could have significant implications for stakeholders.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company dedicated to improving the lives of patients suffering from rare, debilitating, and life-threatening diseases. The company focuses on developing and commercializing a portfolio of innovative protein replacement therapies and precision medicines, including small molecules and biologics. Headquartered in Leiden, the Netherlands, Pharming operates across over 30 markets worldwide, including North America, Europe, the Middle East, Africa, and Asia-Pacific.
YTD Price Performance: -3.86%
Average Trading Volume: 1,965
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $632.2M
Learn more about PHGUF stock on TipRanks’ Stock Analysis page.
